Open AccessRate and Predictors of Success in the Retreatment of Chronic Hepatitis C Virus in HIV/Hepatitis C Virus Coinfected Patients With Prior Nonresponse or Relapse
Author(s) -
Pablo Labarga,
Eugenia Vispo,
Pablo Barreiro,
Sonia Rodrı́guez-Nóvoa,
Javier Pinilla,
Judit Morello,
Luz Martín-Carbonero,
Paula Tuma,
José Medrano,
Vincent Soriano
Publication year - 2010
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e3181bd5ce1
Subject(s) - medicine , ribavirin , hepatitis c virus , gastroenterology , pegylated interferon , hepatitis c , confidence interval , viral load , immunology , virus
In hepatitis C virus (HCV)/HIV-coinfected patients who failed a course of suboptimal hepatitis C therapy, retreatment with adequate doses and duration of pegylated interferon (pegIFN) plus ribavirin (RBV) is advisable in the presence of compensated advanced liver fibrosis.